chronic myeloid leukaemia

chronic myeloid leukaemia

An indolent leukaemia, characterised by increased mature granulocytes in the peripheral circulation.

Clinical findings
Often asymptomatic; otherwise with splenomegaly, left sided pain, general malaise, joint pain, low-grade fever, pancytopaenia resulting in increased infections, anaemia, thrombocytopaenia.
 
Genetics
Philadelphia chromosome, a fusion gene bcl-abl from a 9:22 translocation, resulting in a gene product with tyrosine kinase activity.

Management
Imatinib mesylate induces major cytogenetic responses in 60% of patients with chronic-phase CML and complete haematologic responses in 95% of CML patients.

chronic myeloid leukaemia

A myeloproliferative disorder caused by a constitutively active BCR-ABL tyrosinase kinase. It has been found that continuous treatment of chronic phase chronic myeloid leukaemia with the drug imatinib can induce durable responses of five years or more in a high proportion of patients
References in periodicals archive ?
dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec [sup.
This guideline was developed to address the diagnosis and management of chronic myeloid leukaemia (CML) in the South African setting, with particular reference to the prescribing of BCRABL tyrosine kinase inhibitors (TKIs), and the management of their side-effects.
In July 2003 Thomas was diagnosed with potentially life threatening chronic myeloid leukaemia.
Trials have already begun on a small number of sufferers of chronic myeloid leukaemia to ensure the technique is safe and effective.
The drug is designed to tackle chronic myeloid leukaemia (CML), a common and potentially fatal form of the disease, by 'correcting' a genetic abnormality in bone marrow.
A proportion of patients with chronic myeloid leukaemia (CML) remained completely free of the disease two years after doctors stopped treating them, the findings showed.
Tests had revealed that the 48-year-old, from Forest Hall, North Tyneside, had chronic myeloid leukaemia and treatment had to start immediately for him to have a chance of survival.
In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.
on what they propose as chakalaka-induced vasodilatation in a series of patients with chronic myeloid leukaemia on tyrosine kinase inhibitors (TKIs).
The All Wales Medicines Strategy Group has said Sprycel - also known as dasatinib - should be used in the treatment of adults with chronic or accelerated phase chronic myeloid leukaemia (CML), if they are resistant to another drug.

Full browser ?